Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $37.41M rose 73.9% year over year, behind the +418.0% change in trailing-twelve-month net income. Sequentially, it rose 8.9% from the prior quarter.

Context

  • Net income amounted to 101.5% of revenue in FY2025, up 99.0 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of $131.56M (-54.2%) for the fiscal year ending Dec 2026, a slowdown from the +4893.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$37.41M+8.9% QoQ
Last fiscal yearDec 2025
$287.2M+4893.1% YoY
LTMJun 2026
$314.11M+418.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.9%-5.7%-79.7 pp
1 year+4893.1%-54.2%-4947.3 pp
3-year CAGR—-14.5%—
5-year CAGR-1.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
287.2M USD
Year-over-year change
+4893.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 net income of $314.11M is the 4th largest of the 10 companies compared; the peer median is $166.09M.
  • Its year-over-year change of +418.0% is the highest of 9, against a peer median of +55.8%.
  • Net income amounts to 100.8% of revenue for AUPH, versus a peer median of 2671.8%.
AUPH Competitors Peer median
Net Income for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$586.84M -23.5%+9.0%—
ALMSAlumis Inc. Common StockLTM Jun 2026$438.96M +92.9%+29.5%5933.5%
VERAVera Therapeutics, Inc.LTM Jun 2026$401.9M +84.1%+49.8%—
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$314.11M +418.0%—100.8%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$259.47M +76.5%+66.1%—
TRAXFirst Tracks Biotherapeutics IncFY2025$166.09M +1.5%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$78.15M +141.3%-19.7%—
EVMNEvommune, Inc.LTM Mar 2026$75.99M ——759.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M -46.5%-9.3%832.6%
ATTOAttovia Therapeutics, Inc.FY2025$60.9M +35.2%—4511.0%
Peer median (excluding AUPH) $166.09M+55.8%+19.3%2671.8%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
Deferred Income Tax0000(176.19M)
Stock-Based Compensation31.24M32.3M45.31M31.6M14.68M
Change in Working Capital(21.63M)(6.82M)(5.61M)5.45M(8.78M)
Accounts Receivables(15.42M)1.93M(10.61M)(12.46M)(4.91M)
Inventory(5.64M)(9.07M)(15.87M)477K(6.46M)
Accounts Payables4.08M(792K)1.24M860K(1.87M)
Other Working Capital(4.65M)1.12M19.63M16.57M4.46M
Other Non-Cash Items10.9M462K(6.79M)(17.85M)9.49M
Operating Cash Flow(157.69M)(79.53M)(33.46M)44.39M135.66M
Capital Expenditures(1.5M)(292K)(718K)(281K)(252K)
Acquisitions (Net)(1.2M)0000
Purchases of Investments(438.96M)(523.99M)(523.5M)(545.83M)(526.65M)
Sales of Investments354.43M464.32M529.38M585.42M494.13M
Other Investing Activities(16.63M)(663K)(11.86M)(43K)0
Investing Cash Flow(103.87M)(60.63M)(6.71M)39.26M(32.77M)
Debt Repayment00(10.03M)(11.99M)(13.14M)
Common Stock Issued196.74M00014.95M
Common Stock Repurchased000(40.24M)(98.16M)
Dividends Paid00000
Other Financing Activities24.37M2.43M4.9M3.14M(9.76M)
Financing Cash Flow221.11M2.43M(5.13M)(49.09M)(106.11M)
Effect of Forex Changes00000
Net Change in Cash(40.45M)(137.73M)(45.3M)34.56M(3.22M)
Free Cash Flow(159.19M)(79.82M)(34.18M)44.11M135.41M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.